Peter Rahmer sold $9,823 of RLAY
See remarks at Relay Therapeutics, Inc.. 1,621 shares at an average of $6.06, traded Oct 28, 2024, filed Oct 30, 2024.
Score components
- +15RoleOfficer
- 0Trade size$10k at market
- 0Share of holdings soldSold 0.4% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -17.7%, 3m -21.5%, 6m -41.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-118985, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 28, 2024 | SOpen-market sale Common Stock | -1,621 | $6.06 | $9,823 | 390,063 | Oct 30, 2024 |
Related signals
Other insiders at Relay Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $329k 17,717 shares | -14% | |
| Pro nowfree Oct 15, 2026 | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $872k 48,199 shares | -9% | |
| 26Weak | Relay Therapeutics, Inc. | Donald A Bergstrom President, R&D | $162k 8,530 shares | -2% | |
| 37Weak | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $336k 17,717 shares | -13% | |
| 44Moderate | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $913k 48,199 shares | -8% | |
| 19Weak | Relay Therapeutics, Inc. | Peter Rahmer See remarks | $90k 4,508 shares | -2% | |
| 57Moderate | Relay Therapeutics, Inc. | SVF Pauling (Cayman) Ltd owner | $116M 6,000,000 shares | -22% | |
| 37Weak | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $350k 17,717 shares | -11% | |
| 45Moderate | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $980k 48,199 shares | -8% | |
| 41Moderate | Relay Therapeutics, Inc. | Donald A Bergstrom President, R&D | $42k 2,237 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.